^
Association details:
| Biomarker: | EGFR R521K |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 1863: Correlations of genetic variation R521K of EGF receptor and the in vitro, in vivo and clinical phenotypes of head and neck cancers after cetuximab treatment
Published date:
05/15/2020
Excerpt:
Our clinical study, showed significantly lower progression-free survival among patients with R521K tumors.
DOI:
10.1158/1538-7445.AM2020-1863
Source:
Title:
Abstract 1863: Correlations of genetic variation R521K of EGF receptor and the in vitro, in vivo and clinical phenotypes of head and neck cancers after cetuximab treatment
Published date:
05/15/2020
Excerpt:
...in vivo xenograft models showed strong antitumor effect of cetuximab in wild type models, and only moderate or no response in EGFR R521K models.
DOI:
10.1158/1538-7445.AM2020-1863
